Myeloid cell leukemia-1 expression in cancers of the oral cavity: a scoping review
- PMID: 35524332
- PMCID: PMC9074253
- DOI: 10.1186/s12935-022-02603-0
Myeloid cell leukemia-1 expression in cancers of the oral cavity: a scoping review
Abstract
Background: B cell lymphoma-2 (Bcl-2) family members play important roles in cell survival as well as cell death. The role of myeloid cell leukemia-1 (Mcl-1), an important member of the Bcl-2 family, is well established in hematopoietic malignancies. However, the association between Mcl-1 and oral cavity, cancers is not clearly defined.
Methods: A scoping review was conducted until June 30, 2021, using four major databases, PubMed, Scopus, Web of Science, and Embase. Medical subject headings keywords for Mcl-1, along with its other identifiers, and head and neck cancers (only oral cavity tumors) were used to evaluate the expression, function, molecular association, and therapeutic approach of Mcl-1 in oral cavity cancers and precancers.
Findings: Mcl-1 expression was associated with the progression of oral cavity cancers. The molecular mechanism and pathways of Mcl-1 in oral cavity cancers established via experimental results have been highlighted in this review. Moreover, the various synthetic and naturally derived therapeutic agents targeting Mcl-1 have been documented.
Novelty/improvement: Based on our present review, Mcl-1 appears to be an effective anticancer target that can be used in the therapeutic management of oral cancers.
Keywords: Agents targeting Mcl-1; Cancer; Mcl-1; Oral cavity.
© 2022. The Author(s).
Conflict of interest statement
The authors declare the absence of any competing interests.
Figures



Similar articles
-
Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers.PLoS One. 2014 Nov 19;9(11):e111927. doi: 10.1371/journal.pone.0111927. eCollection 2014. PLoS One. 2014. PMID: 25409302 Free PMC article.
-
Myeloid cell leukemia-1: a formidable barrier to anticancer therapeutics and the quest of targeting it.Explor Target Antitumor Ther. 2022;3(3):278-296. doi: 10.37349/etat.2022.00083. Epub 2022 May 24. Explor Target Antitumor Ther. 2022. PMID: 36045907 Free PMC article. Review.
-
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.Cancer Biol Ther. 2005 Mar;4(3):267-76. doi: 10.4161/cbt.4.3.1496. Epub 2005 Mar 20. Cancer Biol Ther. 2005. PMID: 15753661
-
Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.Int J Biol Macromol. 2021 Sep 30;187:999-1018. doi: 10.1016/j.ijbiomac.2021.07.166. Epub 2021 Jul 30. Int J Biol Macromol. 2021. PMID: 34339789 Review.
-
Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.Curr Med Chem. 2017;24(40):4488-4514. doi: 10.2174/0929867324666170912092659. Curr Med Chem. 2017. PMID: 28901269 Review.
Cited by
-
Podophyllotoxin reduces the aggressiveness of human oral squamous cell carcinoma through myeloid cell leukemia‑1.Int J Mol Med. 2023 Nov;52(5):103. doi: 10.3892/ijmm.2023.5306. Epub 2023 Sep 15. Int J Mol Med. 2023. PMID: 37711052 Free PMC article.
-
Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis.Cell Oncol (Dordr). 2025 Feb;48(1):123-138. doi: 10.1007/s13402-024-00962-6. Epub 2024 Jun 18. Cell Oncol (Dordr). 2025. PMID: 38888847 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A, Cancer statistics. 2020. CA Cancer J Clin. 2020;70:7–30. - PubMed
-
- Pons Vicente O, Almendros Marqués N, Berini Aytés L. Gay Escoda C Minor salivary gland tumors: a clinicopathological study of 18 cases. Med Oral Patol Oral Cir Bucal. 2008;13:E582-8. - PubMed
-
- Wetzel SL, Wollenberg J. Oral potentially malignant disorders. Dent Clin North Am. 2020;64:25–37. - PubMed
Publication types
LinkOut - more resources
Full Text Sources